Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

476 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Morgan TM, et al. J Urol. 2024 Apr;211(4):526-532. doi: 10.1097/JU.0000000000003890. Epub 2024 Feb 29. J Urol. 2024. PMID: 38421252
Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Morgan TM, et al. J Urol. 2024 Apr;211(4):509-517. doi: 10.1097/JU.0000000000003892. Epub 2024 Feb 29. J Urol. 2024. PMID: 38421253
Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
Drost FH, Nieboer D, Morgan TM, Carroll PR, Roobol MJ; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP) Consortium. Drost FH, et al. Among authors: morgan tm. Eur Urol. 2019 Nov;76(5):693-702. doi: 10.1016/j.eururo.2019.07.041. Epub 2019 Aug 24. Eur Urol. 2019. PMID: 31451332
Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis.
Singhal U, Nallandhighal S, Tosoian JJ, Hu K, Pham TM, Stangl-Kremser J, Liu CJ, Karim R, Plouffe KR, Morgan TM, Cieslik M, Lucianò R, Shariat SF, Finocchio N, Dambrosio L, Doglioni C, Chinnaiyan AM, Tomlins SA, Briganti A, Palapattu GS, Udager AM, Salami SS. Singhal U, et al. Among authors: morgan tm. Nat Commun. 2024 May 21;15(1):4341. doi: 10.1038/s41467-024-48629-y. Nat Commun. 2024. PMID: 38773085 Free PMC article.
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.
Tosoian JJ, Zhang Y, Xiao L, Xie C, Samora NL, Niknafs YS, Chopra Z, Siddiqui J, Zheng H, Herron G, Vaishampayan N, Robinson HS, Arivoli K, Trock BJ, Ross AE, Morgan TM, Palapattu GS, Salami SS, Kunju LP, Tomlins SA, Sokoll LJ, Chan DW, Srivastava S, Feng Z, Sanda MG, Zheng Y, Wei JT, Chinnaiyan AM; EDRN-PCA3 Study Group. Tosoian JJ, et al. Among authors: morgan tm. JAMA Oncol. 2024 Apr 18. doi: 10.1001/jamaoncol.2024.0455. Online ahead of print. JAMA Oncol. 2024. PMID: 38635241
Variation in management of lymph node positive prostate cancer after radical prostatectomy within a statewide quality improvement consortium.
Triner D, Daignault-Newton S, Singhal U, Sessine M, Dess RT, Caram MEV, Borza T, Ginsburg KB, Lane BR, Morgan TM; Michigan Urological Surgery Improvement Collaborative. Triner D, et al. Among authors: morgan tm. Urol Oncol. 2024 Jul;42(7):220.e1-220.e8. doi: 10.1016/j.urolonc.2024.03.015. Epub 2024 Apr 2. Urol Oncol. 2024. PMID: 38570271
476 results